Benitec Biopharma (BNTC) News Today $13.93 -0.05 (-0.36%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BNTC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Equities Analysts Offer Predictions for BNTC FY2025 EarningsMay 20 at 2:37 AM | americanbankingnews.comBenitec Biopharma Inc. (NASDAQ:BNTC) is Suvretta Capital Management LLC's 5th Largest PositionSuvretta Capital Management LLC lifted its stake in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 1.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,960,009 shares of the biotechnology company's stockMay 19 at 7:37 AM | marketbeat.comBenitec Biopharma's (BNTC) Market Outperform Rating Reiterated at JMP SecuritiesMay 18 at 2:45 AM | americanbankingnews.comJanus Henderson Group PLC Purchases 1,739,904 Shares of Benitec Biopharma Inc. (NASDAQ:BNTC)Janus Henderson Group PLC grew its position in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 198.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,616,427 shares of the biotechnology compMay 17, 2025 | marketbeat.comLion Point Capital LP Raises Holdings in Benitec Biopharma Inc. (NASDAQ:BNTC)Lion Point Capital LP boosted its position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 59.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 62,000 shares of the biotechnology company's stock aMay 14, 2025 | marketbeat.comBenitec Biopharma (BNTC) to Release Earnings on MondayBenitec Biopharma (NASDAQ:BNTC) will be releasing earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-benitec-biopharma-inc-stock/)May 7, 2025 | marketbeat.comBenitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Recommendation of "Buy" from AnalystsBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) has been assigned a consensus rating of "Buy" from the nine analysts that are currently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and two have given a strong buy rMay 6, 2025 | marketbeat.com683 Capital Management LLC Acquires Shares of 35,817 Benitec Biopharma Inc. (NASDAQ:BNTC)683 Capital Management LLC bought a new position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 35,817 shares of the biotechnology cMay 5, 2025 | marketbeat.comBenitec Biopharma Inc. (NASDAQ:BNTC) Shares Purchased by Geode Capital Management LLCGeode Capital Management LLC lifted its position in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 134.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 197,096 shares of the biotechnology company'sApril 30, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Has $24.91 Million Stake in Benitec Biopharma Inc. (NASDAQ:BNTC)Adage Capital Partners GP L.L.C. increased its position in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 134.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,972,524 sharesApril 28, 2025 | marketbeat.comMYDA Advisors LLC Acquires New Position in Benitec Biopharma Inc. (NASDAQ:BNTC)MYDA Advisors LLC bought a new position in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 50,000 shares of the biotechnology company's stock, valued at approximately $632,0April 22, 2025 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Stock Crosses Above 50-Day Moving Average - What's Next?Benitec Biopharma (NASDAQ:BNTC) Share Price Crosses Above 50-Day Moving Average - Should You Sell?April 20, 2025 | marketbeat.comBenitec Biopharma Inc. (NASDAQ:BNTC) Sees Large Increase in Short InterestBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 294,200 shares, a growth of 36.1% from the March 15th total of 216,100 shares. Based on an average daily volume of 42,100 shares, the days-to-cover ratio is presently 7.0 days. Approximately 1.3% of the shares of the company are short sold.April 20, 2025 | marketbeat.comBenitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy DeveloperApril 16, 2025 | seekingalpha.comBenitec Biopharma price target raised to $20 from $18 at Citizens JMPApril 12, 2025 | markets.businessinsider.comBenitec Biopharma Inc. (NASDAQ:BNTC) Given Average Rating of "Buy" by BrokeragesShares of Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) have been given an average rating of "Buy" by the nine ratings firms that are covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy ratiApril 10, 2025 | marketbeat.comBenitec Biopharma participates in a conference call with Cantor FitzgeraldApril 8, 2025 | markets.businessinsider.comFranklin Resources Inc. Raises Stock Position in Benitec Biopharma Inc. (NASDAQ:BNTC)Franklin Resources Inc. grew its holdings in Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 269.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,939,287 shares of the biotechnology compaApril 7, 2025 | marketbeat.comLeerink Partnrs Issues Positive Estimate for BNTC EarningsBenitec Biopharma Inc. (NASDAQ:BNTC - Free Report) - Investment analysts at Leerink Partnrs raised their Q3 2025 earnings estimates for Benitec Biopharma in a research report issued on Monday, March 31st. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will earn ($0April 5, 2025 | marketbeat.comInsiders Are Loving These 5 Tech and Biotech StocksApril 2, 2025 | 247wallst.comBenitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Up 23.6% in MarchBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 216,100 shares, an increase of 23.6% from the February 28th total of 174,800 shares. Based on an average trading volume of 50,800 shares, the days-to-cover ratio is presently 4.3 days. Approximately 0.9% of the shares of the stock are short sold.April 2, 2025 | marketbeat.comBenitec Biopharma completes stock and warrant offeringsMarch 30, 2025 | investing.comSuvretta Capital Management, L Acquires 900,000 Shares of Benitec Biopharma Inc. (NASDAQ:BNTC) StockBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) Director Suvretta Capital Management, L purchased 900,000 shares of the stock in a transaction that occurred on Wednesday, March 26th. The stock was bought at an average cost of $13.00 per share, with a total value of $11,700,000.00. Following the completion of the transaction, the director now directly owns 8,793,245 shares in the company, valued at $114,312,185. The trade was a 11.40 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.March 29, 2025 | marketbeat.comBenitec Biopharma inks deal granting stock resale rightsMarch 29, 2025 | investing.comInsider Buying: Benitec Biopharma Inc. (NASDAQ:BNTC) Director Buys 900,000 Shares of StockMarch 29, 2025 | insidertrades.comPiper Sandler Keeps Their Buy Rating on Benitec Biopharma (BNTC)March 28, 2025 | markets.businessinsider.comBenitec Biopharma prices 1.44M shares at $13.00 in underwritten offeringMarch 27, 2025 | markets.businessinsider.comBenitec Biopharma prices $30M securities offeringsMarch 25, 2025 | msn.comBenitec Biopharma's (BNTC) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $28.00 price objective on shares of Benitec Biopharma in a research report on Monday.March 25, 2025 | marketbeat.comBenitec Biopharma Inc. Announces Pricing of $30 Million Common Stock OfferingMarch 25, 2025 | globenewswire.comSimplify Asset Management Inc. Trims Stake in Benitec Biopharma Inc. (NASDAQ:BNTC)Simplify Asset Management Inc. lessened its position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) by 34.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 76,337 shares of the biotechnology company's stoMarch 24, 2025 | marketbeat.comBenitec Biopharma Reports Positive Interim Results For BB-301 Gene Therapy In OPMD Clinical TrialMarch 22, 2025 | nasdaq.comBenitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Up 17.6% in FebruaryBenitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) saw a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 174,800 shares, an increase of 17.6% from the February 13th total of 148,700 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average trading volume of 49,700 shares, the days-to-cover ratio is currently 3.5 days.March 20, 2025 | marketbeat.comBenitec - Another Biopharma RocketMarch 13, 2025 | talkmarkets.comBenitec Biopharma (NASDAQ:BNTC) Shares Cross Above 50-Day Moving Average - Here's WhyBenitec Biopharma (NASDAQ:BNTC) Shares Cross Above 50-Day Moving Average - What's Next?March 12, 2025 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Share Price Passes Above Fifty Day Moving Average - Here's What HappenedBenitec Biopharma (NASDAQ:BNTC) Shares Cross Above 50-Day Moving Average - Here's WhyMarch 4, 2025 | marketbeat.comBenitec Biopharma to Participate in Upcoming Conferences in MarchFebruary 26, 2025 | markets.businessinsider.comPiper Sandler Sticks to Their Buy Rating for Benitec Biopharma (BNTC)February 26, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Benitec Biopharma (NASDAQ:BNTC)HC Wainwright restated a "buy" rating and set a $28.00 target price on shares of Benitec Biopharma in a report on Friday.February 22, 2025 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Benitec Biopharma (BNTC), Halozyme (HALO)February 19, 2025 | markets.businessinsider.comBenitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Rating of "Buy" from AnalystsShares of Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) have received an average recommendation of "Buy" from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and two have giFebruary 18, 2025 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Posts Earnings Results, Beats Expectations By $0.19 EPSBenitec Biopharma (NASDAQ:BNTC - Get Free Report) issued its quarterly earnings results on Friday. The biotechnology company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.19.February 15, 2025 | marketbeat.comBenitec Biopharma reports Q2 EPS (33c) vs ($2.64) last yearFebruary 15, 2025 | markets.businessinsider.comBenitec presents new gene therapy data at MD conferenceFebruary 14, 2025 | msn.comBenitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational UpdateFebruary 14, 2025 | globenewswire.comBenitec Biopharma (NASDAQ:BNTC) Shares Pass Below 50-Day Moving Average - Here's WhyBenitec Biopharma (NASDAQ:BNTC) Share Price Passes Below Fifty Day Moving Average - Here's What HappenedFebruary 13, 2025 | marketbeat.comBenitec Biopharma (BNTC) to Release Quarterly Earnings on MondayBenitec Biopharma (NASDAQ:BNTC) will be releasing earnings on Monday, February 10, Financial Modeling Prep reports.February 3, 2025 | marketbeat.comBenitec Biopharma (NASDAQ:BNTC) Shares Pass Above 50 Day Moving Average - Here's What HappenedBenitec Biopharma (NASDAQ:BNTC) Stock Crosses Above 50 Day Moving Average - Here's WhyFebruary 1, 2025 | marketbeat.comFranklin Resources Inc. Acquires Significant Stake in Benitec Biopharma Inc.January 27, 2025 | gurufocus.comBenitec Biopharma to Participate in Upcoming Conferences in January and FebruaryJanuary 27, 2025 | markets.businessinsider.com Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Email Address BNTC Media Mentions By Week BNTC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BNTC News Sentiment▼0.840.65▲Average Medical News Sentiment BNTC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BNTC Articles This Week▼102▲BNTC Articles Average Week Get Benitec Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies JANX News EVO News SPRY News ADPT News VERA News DYN News ANIP News BGM News OCUL News CALT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BNTC) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.